Kenvue (KVUE) stock nudges up as fresh deal scrutiny hits — and the spread traders are watching

Kenvue (KVUE) stock nudges up as fresh deal scrutiny hits — and the spread traders are watching

New York, Jan 8, 2026, 10:57 EST — Regular session

  • Kenvue shares rose in morning trade as deal chatter resurfaced around its pending sale to Kimberly-Clark
  • A shareholder law firm said it was reviewing the transaction and the process behind it
  • Traders are watching the gap between Kenvue’s price and the value implied by the cash-and-stock offer ahead of a late-January vote

Kenvue Inc shares rose 0.8% to $16.87 in mid-morning trade on Thursday after shareholder law firm Kahn Swick & Foti said it was investigating the consumer health group’s pending sale to Kimberly-Clark. The firm said it is reviewing whether Kenvue’s board ran a fair process and secured the best price for shareholders. PR Newswire

The move matters now because Kenvue’s stock has been trading like a deal situation, not a stand-alone story, as investors handicap closing odds and timing. Merger arbitrage — buying the target while hedging the buyer — can keep shares anchored near the offer value, but the gap tends to widen when the finish line is far out.

Under the terms announced in November, Kenvue shareholders would receive $3.50 per share in cash and 0.14625 Kimberly-Clark shares for each Kenvue share held at closing. With Kimberly-Clark up about 1% at $98.52, that package implies roughly $17.91 per Kenvue share, leaving about a 6% discount in Thursday’s trade. PR Newswire

Separately, Kenvue appointed Madhav Nayak as vice president and chief marketing officer for Asia-Pacific. Nayak called the role “an incredible opportunity” to help shape brands including Johnson’s, Neutrogena and Listerine in a “fast-growing” region, according to an account of his remarks. Storyboard18

Consumer staples were mixed on the day. Procter & Gamble rose 1.6%, Haleon slipped 0.4%, and Perrigo gained 1.6%.

Still, the deal’s long runway leaves Kenvue exposed to swings in Kimberly-Clark’s share price and any delays tied to approvals. The company has also faced litigation over products including Tylenol and talc-based baby powder, risks that can reprice quickly when headlines hit. Reuters

Stock Market Today

  • Stoneweg Europe Stapled Trust: 1.6% Five-Year CAGR, Earnings Shrink
    January 9, 2026, 8:23 PM EST. Stoneweg Europe Stapled Trust (SGX: SET) posted a 1.6% five-year CAGR, while earnings have declined. The shares rose 14% in the past three months but are down about 31% over five years. A 6.9% recent uptick could signal momentum, yet the market has not validated higher prices. EPS progress has outpaced the stock only sporadically, and the dividend has fallen, weighing on total returns. The five-year TSR stood at 8.5%, driven mainly by distributions. Year-to-date, the stock is up about 18% including dividends, but this lags the broader market. Analysts flag two risk signs, one of which merits close attention.
AMD stock falls in regular trading as CES AI chip push meets profit-taking ahead of Feb. 3 earnings
Previous Story

AMD stock falls in regular trading as CES AI chip push meets profit-taking ahead of Feb. 3 earnings

Sandisk Corporation stock slides 11% as CES rally cools; BofA lifts target to $390
Next Story

Sandisk Corporation stock slides 11% as CES rally cools; BofA lifts target to $390

Go toTop